Monographs: Dosage forms: Specific monographs: Carbamazepine oral suspension (Carbamazepini suspensio peroralum)

Category. Antiepileptic.

Storage. Carbamazepine oral suspension should be kept in tightly closed, light-resistant containers, protected from freezing and from excessive heat.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 100 mg per 5 mL. Strength in the current WHO EML for children: 100 mg per 5 mL.

Requirements

Complies with the monograph for Liquid preparations for oral use.

Definition. Carbamazepine oral suspension is a suspension of Carbamazepine in a suitable vehicle, which may be flavoured. It contains not less than 90.0% and not more than 110.0% of the amount of carbamazepine (C15H12N2O) stated on the label.

Manufacture. The formulation, manufacturing process and product packaging of Carbamazepine oral suspension are designed and controlled so as to ensure that, at any stage of the life cycle of the product, when tested by a suitable method such as X-ray powder diffractometry, the carbamazepine in the oral suspension is predominantly in the form of anhydrous polymorph form III.

Identity tests

  • Either test A alone or any two of tests B, C and D may be applied.

Transfer a quantity of the oral suspension equivalent to about 0.25 g of carbamazepine to a centrifuge tube, centrifuge and wash the precipitate with two quantities of 10 mL of water R. Dissolve the precipitate as completely as possible in 10 mL of dichloromethane R, filter and evaporate the filtrate to dryness in air, dry the residue at 80°C for 30 minutes and use it for the following tests.

A. Carry out the examination with the residue as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from carbamazepine RS or with the reference spectrum of carbamazepine.

B. Carry out the test as described under 1.14.1 Chromatography, Thin-layer chromatography using silica gel R6 as the coating substance and a mixture of 78 volumes of toluene R and 22 volumes of methanol R as the mobile phase. Apply separately to the plate 2 μL of each of the following three solutions, prepared using as a solvent in a mixture of equal volumes of ethanol (~750 g/L) TS and dichloromethane R. For solution (A) use 5 mg of the residue per mL. For solution (B) use 5 mg of carbamazepine RS per mL. For solution (C) use 5 mg of carbamazepine RS and 5 mg of diazepam R per mL. After removing the plate from the chromatographic chamber allow it to dry in air and examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid unless the chromatogram obtained with solution (C) shows 2 clearly separated spots.

C. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under “Assay”, method B. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to carbamazepine in the chromatogram obtained with solution (2).

D. Heat 0.1 g of the residue with 2 mL of nitric acid (~1000 g/L) TS in a water-bath for 3 minutes; an orange-red colour is produced.

pH value (1.13). pH of the oral suspension, 3.5–4.5.

Impurity D . Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given below under Assay B.

Prepare the following solutions. For solution (1), if necessary, shake the container of oral suspension to resuspend any settled material. Transfer a quantity of it, containing about 0.2 g of Carbamazepine, into a 100 mL volumetric flask, add 50 mL of methanol R and sonicate for about 15 minutes. Allow the suspension to cool to room temperature and dilute to volume with water R. Centrifuge 10 mL of the suspension. Transfer 5.0 mL of the supernatant to a 10 mL volumetric flask and dilute to volume with equal volumes of methanol R and water R. For solution (2) dilute 1 volume of solution (1) to 500 volumes with equal volumes of methanol R and water R. For solution (3) use a solution containing 10 µg of carbamazepine RS and 10 µg of carbamazepine impurity A RS per mL of a mixture of equal volumes of methanol R and water R.

Inject 20 μL of solution (3). The test is not valid unless the resolution between carbamazepine and carbamazepine impurity A is not less than 1.7.

Inject alternately 20 μL each of solution (1) and solution (2). Record the chromatograms for four times the retention time of carbamazepine. In the chromatogram obtained with solution (1) the following impurity, if present, is eluted at the following relative retention with reference to carbamazepine (retention time about 9 minutes): impurity D about 2.1.

In the chromatogram obtained with solution (1):

  • the area of any peak corresponding to impurity D, when multiplied by a correction factor of 0.4, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%).

Dissolution. [Note from the Secretariat. It is intended to add a dissolution test.]

Assay

  • Either method A or B may be applied.

A. If necessary, shake the container of oral suspension to resuspend any settled material. Transfer an accurately weighed quantity of it, containing about 0.1 g of Carbamazepine, to a 100 mL volumetric flask, add about 50 mL of ethanol (~750g/L) TS and sonicate for about 15 minutes. Allow the suspension to cool to room temperature, dilute with the same solvent to volume and filter the solution. Dilute 1.0 mL of the filtrate to 100.0 mL with ethanol (~750g/L) TS.

Measure the absorbance of a 1 cm layer of the solution at the maximum at about 285 nm against a solvent cell containing ethanol (~750 g/L) TS. Determine the weight per mL (1.3.1) of the oral suspension and calculate the content of C15H12N2O, weight in volume, of the oral suspension using the absorptivity value of 49.0 ( = 490).

B. Carry out the test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (25 cm x 4.6 mm), packed with particles of silica gel, the surface of which has been modified with chemically-bonded cyanopropyl groups (10 μm). As the mobile phase use a mixture of 30 volumes of tetrahydrofuran R, 120 volumes of methanol R, 850 volumes of water R, 0.2 volume of anhydrous formic acid R and 0.5 volume of triethylamine R.

Operate with a flow rate of 2.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 230 nm.

Prepare the following solutions. For solution (1), if necessary, shake the container of oral suspension to resuspend any settled material. Transfer an accurately weighed quantity of it, containing about 200 mg of Carbamazepine, to a 100 mL volumetric flask, add 50 mL of methanol R and sonicate for about 15 minutes. Allow the suspension to cool to room temperature, dilute to volume with water R and filter the solution. Dilute 5.0 mL of the filtrate to 50.0 mL with equal volumes of methanol R and water R. For solution (2) use carbamazepine RS to obtain a solution containing 0.2 mg per mL of equal volumes of methanol R and water R.

Inject alternately 20 µL each solution (1) and (2). The assay is not valid unless the column efficiency is at least 5000, determined for the peak due to carbamazepine in the chromatogram obtained with solution (2).

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2). Determine the weight per mL (1.3.1) of the oral suspension and calculate the content of carbamazepine (C15H12N2O), weight in volume, of the oral suspension using the declared content of C15H12N2O in carbamazepine RS.

Impurities. The impurity limited by the requirements of this monograph is impurity D listed in the monograph for carbamazepine.

to previous sectionto next section